Mercado de tratamiento del linfedema en América del Norte: tendencias de la industria y pronóstico hasta 2029

Análisis y perspectivas del mercado de tratamiento del linfedema en América del Norte

El linfedema suele afectar uno de los brazos o las piernas. En algunos casos, pueden verse afectados ambos brazos y piernas. Algunos pacientes pueden experimentar hinchazón en la cabeza, los genitales o el pecho.

El linfedema es incurable, pero se puede controlar mediante el tratamiento adecuado, que puede ayudar a reducir la hinchazón y el dolor.

Terapia descongestiva compleja (TCC): comienza con una fase de terapia intensiva, durante la cual el paciente recibe tratamiento y entrenamiento diarios. A esto le sigue la fase de mantenimiento, en la que se anima al paciente a hacerse cargo de su cuidado utilizando las técnicas que le han enseñado.

Las mutaciones pueden causar linfedema primario en algunos de los genes implicados en el desarrollo del sistema linfático. Estos genes defectuosos interfieren en el desarrollo del sistema linfático, minando su capacidad para drenar el líquido adecuadamente.

El linfedema secundario tiene varias causas posibles, entre ellas, cirugía oncológica, radioterapia, infecciones, enfermedades inflamatorias, enfermedades cardiovasculares, lesiones y traumatismos.

La creciente prevalencia de cánceres y el aumento del gasto sanitario han acelerado la necesidad de tratar el linfedema en los centros sanitarios. El auge de las innovaciones y las tecnologías también está impulsando el crecimiento del mercado.

El mercado de tratamiento del linfedema en América del Norte está creciendo en el año de pronóstico debido al aumento de los participantes en el mercado y la disponibilidad de productos de diagnóstico por imagen avanzados. Junto con esto, los fabricantes están involucrados en actividades de I+D para lanzar productos novedosos al mercado.

El creciente número de pacientes con linfedema relacionado con el cáncer en todo el mundo y el aumento de las actividades de I+D están impulsando la demanda del mercado de tratamiento del linfedema en América del Norte en el período de pronóstico. Sin embargo, la falta de cura y el alto costo del tratamiento pueden obstaculizar el crecimiento del mercado de tratamiento del linfedema en América del Norte en el período de pronóstico.

Data Bridge Market Research analiza que el mercado de tratamiento del linfedema de América del Norte crecerá a una CAGR del 9,7 % durante el período de pronóstico de 2022 a 2029.

Market Definition

Lymphedema refers to tissue swelling caused by an accumulation of protein-rich fluid usually drained through the body's lymphatic system. It most commonly affects the arms or legs but can also occur in the chest wall, abdomen, neck, and genitals.

Lymph nodes are an important part of your lymphatic system. Lymphedema can be caused by cancer treatments that remove or damage your lymph nodes. Any problem that blocks the drainage of lymph fluid can cause lymphedema.

Treatment may include compression bandages, massage, compression stockings, sequential pneumatic pumping, careful skincare, and surgery to remove swollen tissue or create new drainage routes.

The high prevalence of cancers, increasing innovations and technologies and rising number of players in the market, and novel product launches also propel the market's growth.

North America Lymphedema Treatment Market Dynamics

Drivers

• Rise in the number of Lymphedema Cases

The collection of lymph fluid in fatty tissues close beneath the skin is called lymphedema. The ailment is caused by a person's poor lymphatic system flow, and it manifests itself in the legs, arms, or both. Primary lymphedema affects one to two million persons in the United States, while secondary lymphedema affects two to three million.

• Increase in the Prevalence of Cancers

According to the National Cancer Institute, 1,806,590 new cancer cases will be identified in the United States in 2020, with 606,520 people dying from the disease.

According to the American Cancer Society, Inc, cancer is the main cause of death in Canada and the second-highest cause in the United States, behind heart disease. In 2018, it was anticipated that 1.9 million new cancer cases and 693,000 cancer deaths would occur in North America.

Furthermore, an increasing number of healthcare facilities and multiple therapies are the factors that will expand the lymphedema treatment market.  Additionally, the healthcare system requires highly advanced treatment products. Therefore, major players are highly focused on new and innovative product launches and approvals to drive the North America lymphedema treatment market. 

Opportunities

• Drug Approvals

The market has witnessed numerous drug approvals in past years, driven by the increasing fatality rate of disease. Increasing drug approvals will ramp up the demand for the lymphedema treatment market.

In July 2015, Siltuximab was the first drug to be approved to treat multicentric castleman's disease under the FDA priority review program in the US. The multicentric castleman's disease enlarges the lymph nodes with characteristic findings in multiple lymph node regions.

Moreover, partnerships and agreements by major players in North America will boost new opportunities for the market's growth rate.

Restraints/Challenges

However, the high cost of treatment and lack of awareness about lymphedema restrains the market. Furthermore, no permanent cure for lymphedema and difficult reimbursement act as the challenge for the North America lymphedema treatment market

North America lymphedema treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market, contact Data Bridge Market Research for an Analyst Brief; our team will help you make an informed market decision to achieve market growth.

COVID-19 Impact on North America Lymphedema Treatment Market

COVID-19 has positively affected the market. On March 11, 2020, COVID-19 was formally declared a pandemic. The COVID-19 pandemic has resulted in an unprecedented demand for healthcare resources since then.

The treatment of both primary and secondary lymphedema patients has been interrupted or delayed during COVID 19. There was a huge decrease in the number of patients visiting hospitals, which impacted the overall growth of the North America lymphedema treatment market. The COVID-19 impact has negatively affected the price of lymphedema treatment products because of the increased cost of drugs and medication prescribed for lymphedema and fewer doctor visits during the lockdown period.

According to United Nations Office on Drugs and Crime (UNODC), mobility restrictions, closed borders, and a decline in overall world trade during COVID-19 disrupted the supply chains of drug markets.

Moreover, many drugs are being produced at different locations, and due to the restrictions on movement, there has been a shortage in the drug supply. Therefore, COVID-19 has a negative impact on the supply chain of the North America lymphedema treatment market.

Recent Developments

• In February 2020, Avet Pharmaceuticals Inc. announced that they acquired a portfolio of 23 abbreviated new drug applications (ANDAs), covering 17 product families, all previously approved by the U.S. Food and Drug Administration (FDA). This broadened the product portfolio of the company
• In September 2021, Tactile Medical announced the enrollment of the first patient in a randomized, controlled clinical trial evaluating the effectiveness of Flexitouch plus for the treatment of head and neck lymphedema. This will increase the credibility of the company in the market

North America Lymphedema Treatment Market Scope

North America lymphedema treatment market is segmented based on treatment type, type, affected area, age group, route of administration, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment Type

• Compression Therapy
• Surgery
• Drug Therapy
• Laser Therapy
• Others

On the basis of treatment type, the North America lymphedema treatment market is segmented into compression therapy, surgery, drug therapy, laser therapy, and others.

Type

• Secondary Lymphedema
• Primary Lymphedema

On the basis of type, the North America lymphedema treatment market is segmented into secondary lymphedema and primary lymphedema.

Affected Area

• Lower Extremity
• Upper Extremity
• Genitalia

On the basis of affected area, the North America lymphedema treatment market is segmented into lower extremity, upper extremity, and genitalia

Age Group

• Adult
• Geriatric
• Pediatric

On the basis of age group, the North America lymphedema treatment market is segmented into adult, geriatric, and pediatric.

Route of Administration

• Oral
• Injectable
• Topical

On the basis of route of administration, the North America lymphedema treatment market is segmented into oral, injectable, and topical.

End User

• Hospital
• Speciality Clinics
• Ambulatory Surgical Centers
• Others

Based on end user, the North America lymphedema treatment market is segmented into hospital, speciality clinics, ambulatory surgical centers, and others.

Distribution Channel

• Pharmacy Stores
• Direct Tender
• Others

Based on distribution channel, the North America lymphedema treatment market is segmented into pharmacy stores, direct tender, and others.

North America Lymphedema Treatment Market Regional Analysis/Insights

North America lymphedema treatment market is analyzed, and market size insights and trends are provided by country, treatment type, type, affected area, age group, route of administration, end user, and distribution channel as referenced above.

The countries covered in the North America lymphedema treatment market report are the U.S., Canada, and Mexico.

U.S. is expected to dominate the North America lymphedema treatment market due to the strong presence of market players and the rising prevalence of lymphedema diseases.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North American brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels is considered while providing forecast analysis of the country data.

Competitive Landscape and North America Lymphedema Treatment Market Share Analysis

North America lymphedema treatment market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North American presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points are only related to the companies' focus on the North America lymphedema treatment market.

Some of the major players operating in the North America lymphedema treatment market are Tactile Medical, BIOCOMPRESSION SYSTEMS, Lohmann & Rauscher GmbH & Co. KG, ThermoTek, Essity (BSN medical GmbH), Cardinal Health, Smith+Nephew, Avet Pharmaceuticals Inc., KOYA MEDICAL, SIGVARIS GROUP, AIROS Medical, Inc., Tactile Medical, medi GmbH & Co. KG, PAUL HARTMANN AG, Convatec Inc., 3M, JUZO, Mego Afek ltd, Huntleigh Healthcare Limited, HERANTIS PHARMA Plc, among others.

Research Methodology

La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con tamaños de muestra grandes. Los datos del mercado se analizan y estiman utilizando modelos estadísticos y coherentes del mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta. La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Aparte de esto, los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de la línea de tiempo del mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de la participación de mercado de la empresa, estándares de medición, África versus región y análisis de la participación de los proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.

SKU-66841